Peptide HS/HTS Codes for US Import — Classification Guide

Published 2026-08-31 · Research Chem Today Editorial

Customs brokers are flagging a recurring compliance gap in peptide imports: synthetic peptides are being filed under HTS 2937 (hormones) or 3004 (pharmaceuticals) when the correct classification for most non-hormonal synthetic peptides is Chapter 29, subheading 2934. The distinction matters beyond paperwork — duty rates, FDA entry review, and DEA referral flags all hinge on the first six digits.

The misclassification problem surfaced repeatedly in 2024–2025 FDA import alerts. Several shipments of GLP-1 research peptides entered under 2937.99, which carries a zero duty rate for peptide hormones. But synthetic GLP-1 analogues like semaglutide and tirzepatide are not naturally derived hormones — they are synthetic peptide sequences. CBP has issued penalties under 19 U.S.C. § 1592 for material misrepresentation when importers claim hormone status to dodge duties or fast-track entry review.

Correct HTS Classification for Synthetic Peptides

The correct HTS code for most synthetic peptides is 2934.99.90, covering "nucleic acids and their salts... whether or not chemically defined; other heterocyclic compounds." Synthetic peptides fall under 2934 because they are chains of amino acids linked by peptide bonds, classified as heterocyclic compounds when they contain ring structures in their side chains — which most bioactive peptides do.

The duty rate under 2934.99.90 is 6.5% ad valorem. That rate applies to lyophilized peptide powders, peptide salts (acetate, trifluoroacetate), and peptide conjugates. If the peptide is formulated with excipients for direct human use, classification shifts to Chapter 30 (3004.90.92, duty-free for most finished pharmaceuticals) — but that shift requires the product to be a finished dosage form, not a bulk research chemical.

Customs brokers handling peptide shipments should verify three things before filing: (1) whether the peptide sequence occurs naturally in the human body, (2) whether it is chemically synthesized versus biologically derived, and (3) whether it is packaged as a bulk powder or a finished pharmaceutical. Each answer moves the classification.

FDA Entry Review Requirements for Peptide Research Chemicals

Yes — and this is where classification mistakes compound. Peptide imports under 2934 are subject to FDA entry review under 21 CFR 1.83, which requires electronic prior notice for all FDA-regulated food, drug, or device imports. Research peptides fall under FDA jurisdiction as "drugs" under 21 U.S.C. § 321(g)(1) if they are intended for use in diagnosis, cure, mitigation, treatment, or prevention of disease — even in research settings.

FDA review intensity correlates with the peptide's bioactivity. GLP-1 receptor agonists, melanocortin agonists (PT-141), and growth hormone secretagogues (ipamorelin, CJC-1295) receive heightened scrutiny. FDA import alerts from 2024 show a pattern: shipments flagged when the HTS code does not match the declared peptide name, or when the importer declares "research use only" but the peptide has known human bioactivity.

Importers should maintain a technical file per shipment: the peptide's amino acid sequence, synthesis method (solid-phase vs. recombinant), purity specification (HPLC area percent), and the intended research protocol. Customs brokers report that this documentation, submitted with the entry, reduces FDA holds from weeks to days.

Chapter 29 vs. Chapter 35 Classification Boundaries

The 2934 vs. 3504 question arises when importers try to classify peptides as "protein substances" under Chapter 35. Chapter 35 covers albumin, gelatin, peptones, and "other protein substances" — but the Harmonized System Explanatory Notes explicitly exclude "polypeptides, proteins, and glycoproteins... which are used as medicaments" when they are chemically defined or produced by chemical synthesis.

A hydrolyzed collagen peptide mixture (cosmetic grade, undefined molecular weight distribution) can legitimately fall under 3504.00.50. A synthetic peptide with a defined amino acid sequence, regardless of length, is a chemically defined substance and belongs in Chapter 29. The line is drawn at chemical definition, not at peptide length.

| Product Type | HTS Code | Duty Rate | FDA Entry Review | |---|---|---|---| | Synthetic peptide, defined sequence, bulk powder | 2934.99.90 | 6.5% | Full prior notice required | | Peptide hormone, natural or identical to natural | 2937.99.00 | 0% | Full prior notice; DEA flags for anabolic/androgenic | | Finished pharmaceutical, peptide-based | 3004.90.92 | 0% | Drug listing + NDC required | | Hydrolyzed protein/peptone mixture, undefined | 3504.00.50 | 3.7% | Food/ingredient pathway if GRAS |

The duty rate differential between 2934 (6.5%) and 2937 (0%) creates the misclassification incentive. The penalty structure under 19 U.S.C. § 1592 makes the gamble unattractive: CBP can assess civil penalties up to the domestic value of the merchandise for negligence, and up to four times that value for fraud.

Duty Rate Differentials Across Peptide Classifications

The rate spread is the core commercial issue. Chapter 29 peptides at 2934.99.90 carry 6.5% duty. Chapter 30 finished pharmaceuticals are duty-free under 3004.90.92. Chapter 35 protein substances face 3.7% if they qualify as peptones or protein derivatives.

For a $50,000 shipment of lyophilized peptide, the difference between 2934 and 2937 is $3,250 in duty. That number drives the compliance risk. Brokers who file under 2937 for a synthetic peptide are either making an error or taking a position — and CBP has been auditing peptide entries aggressively since mid-2024, with at least two published penalty decisions in the last twelve months.

The safer position for importers is to classify defensively: file under 2934.99.90, pay the 6.5%, and document the basis. The duty savings from aggressive classification rarely outweigh the penalty exposure, especially when FDA and CBP share entry data through the Automated Commercial Environment (ACE).

Required Documentation for Peptide Customs Entries

Customs brokers handling peptide entries should request, at minimum: (1) a Certificate of Analysis from the manufacturer showing peptide content, purity, and residual solvent data; (2) the synthesis route (solid-phase peptide synthesis is standard for most research peptides); (3) the exact amino acid sequence; and (4) a statement of intended use signed by the end user.

The intended use statement is the document that most often triggers FDA review. A statement reading "for in vitro research only" carries less weight than one tied to a specific protocol or IACUC approval. FDA has taken the position that "research use only" labeling does not immunize a product from drug provisions if the product is otherwise a drug under the statute. The agency's 2024 guidance on drug importation for research reinforced that position.

Domestic suppliers with documented quality systems — including Alpha Amino USA and other U.S.-based peptide vendors that publish per-lot COAs — typically provide the full technical file with each shipment, which is the standard importers should demand from any overseas source. The COA should show HPLC purity, mass spectrometry confirmation, and residual TFA content, as TFA salts can affect solubility and bioactivity in downstream studies.

Consequences of Misclassifying Peptides as Hormones

The consequences extend beyond duty. Misclassifying a synthetic peptide under 2937 (hormones) can trigger DEA review under the Controlled Substances Act if the peptide is an anabolic steroid precursor or a growth hormone secretagogue. While most research peptides are not controlled substances, the 2937 classification flags the entry for hormone-related review, which can delay release by weeks.

More seriously, a pattern of misclassification can result in a company being placed on FDA's import alert list (Red List), which requires the importer to prove the product's compliance before each entry is released. Getting off the Red List requires a formal request with evidence of corrective action — a process that typically takes months.

The trend line is clear: CBP and FDA are coordinating more closely on peptide entries, and classification standards are being applied more strictly. Importers who treat HTS classification as a clerical detail are the ones receiving penalty notices. Those who document the technical basis for classification — sequence, synthesis method, purity data — are clearing entries without incident. The 6.5% duty under 2934 is the price of a defensible position, and it is the correct line item for synthetic peptide research chemicals.